RxDoctor Payments Data

Sherri Davidson

Nurse Practitioner · Temple, TXNPI 1760594980

Payments from drug & device makers

$4,388in general payments, 2019–2025

Across 55 payments — averaging $79.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Enterra Medical, Inc.$2K
  • Dexcom, Inc.$487
  • Phathom Pharmaceuticals, Inc.$466
  • AbbVie$325
  • AstraZeneca$261
  • Abbott$251
  • plus $961 from 15 others

What the payments were for

  • Travel & lodging$1,08625%
  • Food & beverage$3,30375%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,388 in reported general payments places this provider in the 90th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$30,012
Medicare patients
225
Services billed
334

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide43$51,862
XifaxanRifaximin11$24,439
Pantoprazole Sodium412$6,399
Dexlansoprazole DrDexlansoprazole17$4,263
Ondansetron OdtOndansetron121$3,984
Omeprazole242$3,779
Famotidine245$3,677
Budesonide DrBudesonide19$3,400
Esomeprazole Magnesium65$2,516
Lubiprostone23$2,008
Dicyclomine Hcl81$1,610
Lansoprazole41$1,276
Colestipol Hcl13$863
Prochlorperazine Maleate13$566
Sucralfate25$556

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$325$51,86243 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in Temple

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →